title: Clusterin may be involved in rat liver allograft tolerance.
abstract: Little is known about the possible role of complement inhibitors on tolerance induced by liver allografts. Clusterin, which is a plasma glycoprotein, inhibits cytolytic membrane attack complex (MAC) of complement by binding to soluble C5b-7 complex. The role of clusterin in relation to the naturally achieved tolerance in a rat orthotopic liver transplantation (OLT) has not been investigated before. Here we determined the kinetics of clusterin expression at different post-transplantation time points in a tolerogenic model (DA-PVG) where rejection was naturally overcome without any immunosuppressive drugs in comparison with the syngenic OLT model (DA-DA). Peripheral blood and liver tissues were taken from OLT at various post-operative time points. A strong expression of soluble clusterin was observed on post-transplantation day 7, which occurred at the peak of the rejection in this tolerogenic OLT model. The expression of clusterin remained strong even after tolerance was achieved. The intensity of clusterin expression was much stronger when compared with the syngenic OLT (DA-DA) model after OLT. A strong expression of clusterin mRNA was also observed in the tolerogenic model on post-OLT day (POD) 7 and the expression persisted when compared with the syngenic model on post-OLT day 60. Our data have shown that the strongest levels of clusterin during the reaction phase in tolerogenic OLT may be involved in tolerance induction.
authors.affiliation: Department of Surgery 1, Nagoya City University Medical School, Nagoya, Japan. kueichen@med.nagoya-cu.ac.jp
authors.forename: K C
authors.initials: KC
authors.lastname: Chiang
authors.forename: S
authors.initials: S
authors.lastname: Goto
authors.forename: C L
authors.initials: CL
authors.lastname: Chen
authors.forename: C L
authors.initials: CL
authors.lastname: Lin
authors.forename: Y C
authors.initials: YC
authors.lastname: Lin
authors.forename: T L
authors.initials: TL
authors.lastname: Pan
authors.forename: R
authors.initials: R
authors.lastname: Lord
authors.forename: C Y
authors.initials: CY
authors.lastname: Lai
authors.forename: H P
authors.initials: HP
authors.lastname: Tseng
authors.forename: L W
authors.initials: LW
authors.lastname: Hsu
authors.forename: T H
authors.initials: TH
authors.lastname: Lee
authors.forename: H
authors.initials: H
authors.lastname: Yokoyama
authors.forename: M
authors.initials: M
authors.lastname: Kunimatsu
authors.forename: Y C
authors.initials: YC
authors.lastname: Chiang
authors.forename: T
authors.initials: T
authors.lastname: Hashimoto
mesh_terms: D000818:Animals; D015152:Blotting, Northern; D051152:Clusterin; D003169:Complement Inactivator Proteins / Q000502:physiology*; D006023:Glycoproteins / Q000502:physiology*; D015151:Immunoblotting; D016031:Liver Transplantation / Q000276:immunology*; D008297:Male; D018832:Molecular Chaperones; D051381:Rats; D016212:Transforming Growth Factor beta / Q000502:physiology; D023001:Transplantation Tolerance; D014184:Transplantation, Homologous; D014409:Tumor Necrosis Factor-alpha / Q000633:toxicity
chemical_list: D051152:Clusterin; D003169:Complement Inactivator Proteins; D006023:Glycoproteins; D018832:Molecular Chaperones; D016212:Transforming Growth Factor beta; D014409:Tumor Necrosis Factor-alpha